期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2009年美国临床肿瘤学会年会热点——小细胞肺癌治疗研究进展 被引量：1

Advance of Treatment of Small Cell Lung Cancer in 2009 American Society of Clinical Oncology Annual Meeting
下载PDF
导出
摘要 肺癌的发病率和死亡率居恶性肿瘤之首,严重威胁人类健康。从生物学行为的角度可将其分为小细胞肺癌（small cell lung cancer,SCLC）和非小细胞肺癌（non-small cell lung cancer,NSCLC）,其中SCLC约占15%-20%。
作者 卢红阳 马胜林 蔡菊芬
机构地区 浙江省肿瘤医院化疗中心
出处 《中国肺癌杂志》 CAS 2009年第9期1047-1050,共4页 Chinese Journal of Lung Cancer
关键词 非小细胞肺癌 临床肿瘤学会年会 治疗 美国 CELL LUNG 生物学行为 恶性肿瘤
分类号 R734.2 [医药卫生—肿瘤] R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Varlotto JM, Recht A, Flickinger JC, et al. Effect of lobectomy on survival in early-stage small cell lung cancer: A retrospective analysis. J Clin Oncol, 2009, 27(suppl): 7585.
  • 2Ross HJ, Mayo Clinic, Scottsdale AZ. Topotecan consolidation after etoposide platinum for limited stage small cell lung cancer patients who do not receive prophylactic cranial irradiation. J Clin Oncol, 2009, 27 (suppl): 7553.
  • 3Komaki R, Paulus R, Ettinger DS, et al. A phase Ii study of accelerated high- dose thoracic radiation therapy (AHTRT) with concurrent chemotherapy for limited small cell lung cancer: RTOG 0239. J Clin Oncol, 2009, 27(suppl): 7527.
  • 4Xia B, Fu X, Cai X, et al. Involved-field radiotherapy for patients with limited small cell lung cancer: Patterns of local-regional failure and feasibility. J Clin Oncol, 2009, 27(suppl): 7554.
  • 5Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med, 2002, 346(2): 85-91.
  • 6Natale RB, Lara PN, Chansky K, et al. A randomized phase Ⅲtrial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC). J Clin Oncol, 2008, 26(suppl): 7512.
  • 7Lara P, Chansky K, Shibata T, et al. Cisplatin _ irinotecan versus cisplatin _ etoposide in extensive stage small cell lung cancer (E-SCLC): Final "common arm": Comparative outcomes analysis of JCOG 9511 and SWOG 0124. J Clin Oncol, 2009, 27(suppl): 8027.
  • 8Sasse Sr EC, Lima Jp, Santos LV, et al. Irinotecan plus platinum analog (IP) compared to etoposide plus platinum analog (EP) in extensive stage small cell lung cancer (ED-SCLC): Systematic review with meta-analysis. J Clin Oncol, 2009, 27(suppl): 8105.
  • 9Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase Ⅲ trial.J Clin Oncol, 2008, 26(26): 4261-4267.
  • 10Schmittel All, Sebastian M, Fischer von Weikersthal L, et al. Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: Results of the German randomized phase III trial. J Clin Oncol, 2009, 27(suppl): 8029.

同被引文献26

  • 1Hanada M, Mizuno S, Fukushima A, et al. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex.JpnJ Cancer Res, 1998, 89(11): 1229-1238.
  • 2Yamamoto M, Takakura A, Masuda N. Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin. Drug Des Devel Ther, 2009, 2: 189-192.
  • 3Chirag MS. Amrubicin: a synthetic anthracyclin analogue in the treatment of extensive stage small cell lung cancer. Recent Pat Anticancer Drug Discov, 2009, 4(3): 241-245.
  • 4Noguchi T, Ichii S, Morisada S, et al. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res, 1998, 89(10): 1055-1060.
  • 5Yamaoka T, Hanada M, Ichii S, et al. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline and its active metabolite amrubicinol on human tumor cells.JpnJ Cancer Res, 1998, 89(10): 1067-1073.
  • 6Matsunaga Y, Hamada A, Okamoto I, et al. Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients. Ther Drug Monit, 2006, 28(1): 76-82.
  • 7Noda T, Watanabe T, Kohda A, et al. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs, 1998, 16(2): 121 - 128.
  • 8Hanada M, Noguchi T, Yamaoka T. Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo. Cancer Sci, 2007, 98(3): 447-454.
  • 9Takigawa N, Takeyama M, Shibayama T, et al. The combination effect of amrubicin with cisplatin or irinotecan for smaLl-ceU lung cancer cells. Oncol Rep, 2006, 15(4): 837-842.
  • 10Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study; Invest New Drugs, 2007, 25(3): 253-258.

引证文献1

二级引证文献6

中国肺癌杂志
2009年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部